A practical guide to prescribing hormone replacement therapy
- PMID: 9664198
- DOI: 10.2165/00003495-199856010-00005
A practical guide to prescribing hormone replacement therapy
Abstract
Over the past 20 years there has been increasing interest in the menopause and hormone replacement therapy (HRT). More recently, postmenopausal HRT has been seen as a specific treatment for symptoms in the short term and preventative therapy in the long term. Women must be counselled regarding the risks and benefits of HRT according to the best available evidence. The patient should also be actively involved in the decision regarding HRT therapy, which should then improve patient compliance. Generally, an appropriate regimen of HRT can be formulated for the majority of patients. Progestogen should be added to therapy in women with an intact uterus in a cyclical or continuous regimen. The management of common estrogenic and progestogenic adverse effects is important in improving compliance. At present, new drugs are being developed for the management of the menopause (selective estrogen receptor modulators and phytoestrogens). Obviously, further research will be necessary to determine whether these drugs have advantages over regular HRT. By offering postmenopausal women HRT an attempt is made to optimise their physical and psychological well-being. However, HRT is not without adverse effects, the most worrying of which is the possible increase in breast cancer risk with long term use. However, with patient education efforts, treatment regimens acceptable to both patient and practitioner can be initiated; in this regard, the aim of the practitioner should be to help the menopausal woman make the decision which is the most appropriate for her.
Similar articles
-
Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.Pharmacoeconomics. 1994 Jun;5(6):513-54. doi: 10.2165/00019053-199405060-00007. Pharmacoeconomics. 1994. PMID: 10147266 Review.
-
Hormone replacement therapy: I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen deficiency.Pharmacoeconomics. 1994 May;5(5):419-45. doi: 10.2165/00019053-199405050-00008. Pharmacoeconomics. 1994. PMID: 10147233 Review.
-
[Indications for hormone replacement therapy].Ther Umsch. 2000 Oct;57(10):635-42. doi: 10.1024/0040-5930.57.10.635. Ther Umsch. 2000. PMID: 11081375 Review. German.
-
Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.Climacteric. 2003 May;6 Suppl 1:11-36. Climacteric. 2003. PMID: 12945798 Review.
-
Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.Climacteric. 2001 Sep;4(3):181-93. Climacteric. 2001. PMID: 11588941 Review.
Cited by
-
Ovarian survival after pelvic radiation: transposition until the age of 35 years.Arch Gynecol Obstet. 2018 Nov;298(5):1001-1007. doi: 10.1007/s00404-018-4883-5. Epub 2018 Sep 14. Arch Gynecol Obstet. 2018. PMID: 30218184 Free PMC article.
-
Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.J Nanosci Nanotechnol. 2015 Sep;15(9):6413-22. doi: 10.1166/jnn.2015.10834. J Nanosci Nanotechnol. 2015. PMID: 26690867 Free PMC article.
-
Long-term hormone therapy for perimenopausal and postmenopausal women.Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5. Cochrane Database Syst Rev. 2017. PMID: 28093732 Free PMC article.
-
Vaginal rings for menopausal symptom relief.Drugs Aging. 2004;21(12):757-66. doi: 10.2165/00002512-200421120-00001. Drugs Aging. 2004. PMID: 15382956 Review.
-
Estradiol-intranasal: a review of its use in the management of menopause.Drugs. 2001;61(15):2243-62. doi: 10.2165/00003495-200161150-00012. Drugs. 2001. PMID: 11772138 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous